Últimas noticias sobre TuHURA Biosciences (NASDAQ:HURA) Bolsa

TuHURA Biosciences

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

TuHURA Biosciences Inc

K92 Mining (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KNT#TSX">KNT</a>) reported quarterly earnings of $0.29 per share. This is a 2800 percent increase over earnings of $0.01 per share from the same period last year. The company reported $144.60 million in sales this quarter. This is a 141.82 percent increase over sales of $59.80 million the same period last year.

Earnings

News

KNTNF

TSX:KNT

K92 Mining Q1 EPS $0.29 Up From $0.01 YoY, Sales $144.60M Up From $59.80M YoY

House Republicans unveiled plans for at least $880 billion in Medicaid cuts late Sunday as the cost-saving centerpiece to fund President Donald Trump&#8216;s $4.5 trillion tax break extension, igniting the largest healthcare battle since the 2017 Obamacare repeal attempt.
What Happened: The legislation, spanning hundreds of pages, would implement new work requirements and eligibility restrictions that Republicans frame as eliminating &#8220;waste, fraud and abuse&#8221; in safety net programs, <a href="https://apnews.com/article/medicaid-cuts-trump-tax-cuts-bill-1e2b12a91a3d12ceb0420ce7053de58e">reported</a> to the Associated Press. 
A Congressional Budget Office (CBO) preliminary analysis estimates 8.6 million Americans could lose healthcare coverage over the next decade.
&#8220;Savings like these allow us to use this bill to renew the Trump tax cuts and keep Republicans&#8217; promise to hardworking middle-class families,&#8221; said Rep. Brett Guthrie (R-KY), chairman of the Energy and Commerce Committee which oversees healthcare spending.
Democrats immediately denounced the proposal. &#8220;In no uncertain terms, millions of Americans will lose their health care coverage,&#8221; said Rep. Frank Pallone (D-NJ), the committee&#8217;s ranking Democrat. &#8220;Hospitals will close, seniors will not be able to access the care they need, and premiums will rise for millions of people if this bill passes.&#8221;
See Also: <a href="https://www.benzinga.com/government/regulations/25/05/45342343/us-stock-futures-rise-as-us-china-agree-to-90-day-tariff-pause-wider-earnings-growth-should-drive-more-balanced-market-performance-says-expert">US Stock Futures Rise As US, China Agree To 90-Day Tariff Pause: &#8216;Wider Earnings Growth Should Drive More Balanced Market Performance,&#8217; Says Expert</a>
Why It Matters: Meanwhile, Democrats have proposed an alternative approach, targeting Medicare Advantage &#8220;upcoding&#8221; practices. Over 40 Democratic lawmakers recently wrote to Republican leadership citing reports that <a href="https://www.benzinga.com/general/health-care/25/05/45313228/democrats-urge-gop-to-target-medicare-advantage-upcoding-instead-of-medicaid-cuts-calling-budget-plan-a-man-made-disaster">Medicare overpaid private insurers by $50 billion in 2024</a> for unverified diagnoses, representing $83 billion in excess payments compared to traditional Medicare.
State budgets are also at risk, with <a href="https://www.benzinga.com/news/25/03/44304047/mark-cuban-warns-nebraska-will-get-crushed-by-tariffs-and-medicaid-cuts-faces-a-200m-shortfall-this-year">Nebraska already facing a $200 million shortfall</a> even before potential Medicaid funding reductions, according to reports cited by entrepreneur Mark Cuban. Combined with recent tariff increases affecting agricultural exports, states heavily dependent on both federal healthcare funding and international trade could face compounded fiscal challenges.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/media/25/05/45342325/first-american-pope-leo-xiv-calls-artificial-intelligence-another-industrial-revolution">First American Pope Leo XIV Calls Artificial Intelligence Another Industrial Revolution</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Health Care

House Republicans Push $880 Billion Medicaid Cuts To Renew Trump Tax Breaks—Democrat Warns: 'Millions Will Lose Their Health Care'

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) with a Outperform and lowers the price target from $20 to $19.

Price Target

Analyst Ratings

ANIK

Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $19

Wellgistics Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>, "Wellgistics Health")), a healthcare infrastructure and pharmaceutical distribution company leveraging proprietary technology, today announced financial results for its first fiscal quarter ended March 31, 2025.
Revenue for the Q1 2025 quarter increased to $10.86 million from zero during the comparable period last year on a GAAP basis. Had the Company acquired Wood Sage and Wellgistics LLC as of January 1, 2024, the $10.86 revenue figure of Q1 2025 would be compared to $7.97 million on a pro forma basis for the same period in 2024, representing approximately a 36% year-over-year increase on a non-GAAP basis.
Wellgistics Health expects continued momentum in Q2, supported by expanded clinical fulfillment capacity, new manufacturer integrations, and scaled deployment of its pharmacy hub platform.
 &nbsp;

WGRX

Wellgistics Health Posts $10.86M Q1 Revenue, Up 36% YoY On Pro Forma Basis

Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) stocks are trading higher on Monday following a major de-escalation in the ongoing U.S.-China trade war.
What Happened: The company's stock gained over 3.21% in Pre-market trading on Monday morning after U.S. Treasury Secretary Scott Bessent announced both sides will reduce tariffs by over 115% for 90 days following negotiations.
U.S. goods will be subjected to a 10% tariff in China, while Chinese imports into the U.S. will face a 30% tariff. Interestingly, China's CCP had prohibited its airlines from importing Boeing planes and <a href="https://www.benzinga.com/25/04/44888512/boeing-jet-returns-to-us-amid-escalating-tariff-tensions-with-china">had sent back</a> the planes following escalating tensions.
Elsewhere, U.S. President Donald Trump also accepted a <a href="https://www.benzinga.com/25/05/45340930/trumps-400-million-boeing-jet-gift-from-qatar-sparks-outcry-from-larry-summers-peter-schiff-banana-republic-level-corruption">$400 million Boeing 747-8 Jumbo Jet</a> from the Qatari royal family, which sparked outrage among experts.
Price Action: Boeing shares were up 3.21% at $201.10 at the time of publication on Wednesday, according to<a href="http://pro.benzinga.com"> Benzinga Pro</a> data.
Photo by BlueBarronPhoto via Shutterstock

Equities

Movers & Shakers

Pre-Market Outlook

Markets

Tech

Boeing Stock Gains Over 3% In Monday Premarket: What's Going On?

HC Wainwright &amp; Co. analyst Andrew Fein maintains Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Buy and lowers the price target from $72 to $68.

HC Wainwright & Co. Maintains Buy on Avidity Biosciences, Lowers Price Target to $68

Mark Zuckerberg may be renowned for creating Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) owned Facebook and shaping the internet as we know it today, but at home, he is like any father trying to ground his daughters in values, family, and reflection. In a podcast, he talked about a bedtime ritual he practices with his daughters, Max and August, which he calls "The Good Night Things."
What Happened: "Every night when I put my daughters to bed, we go through this thing and, like, they call it ‘the good night things,'" Zuckerberg explained <a href="https://www.youtube.com/watch?v=Gf1wzhRnkrc">on</a> the Lex Fridman podcast.
The ritual includes a conversation about four core values that Zuckerberg wants to instill in his children: health, relationships, excitement for the future, and kindness. "What do I want them to remember and just have really ingrained in them as they grow up?" he reflected.
The nightly list starts with health: "Making sure that you take care of yourself and keep yourself in good shape." The second is loving friends and family, which Zuckerberg says is "perhaps one of the most important things." The third something that they are excited about for the future. "I think the way we navigate [life] is that we have things that we&#8217;re looking forward to," he said.
And finally, each night ends with the question: "What did you do today to help someone?" "It can be as simple as, ‘I helped set the table for lunch,'" he said. "But that's sort of like&#8230; if you were to boil down my overall life philosophy into what I try to impart to my kids, those are the things that I think are really important."
See Also: <a href="https://www.benzinga.com/markets/25/05/45286464/bill-gates-commits-99-of-his-remaining-fortune-to-gates-foundation-set-to-wind-down-in-20-years-somebody-should-give-more-money-than-i-did">Bill Gates Commits 99% Of His Remaining Fortune To Gates Foundation, Set To Wind Down In 20 Years: &#8216;Somebody Should&#8230;Give More Money Than I Did&#8217;</a>
Why It Matters: Zuckerberg has presented himself as a ‘family man' in various media appearances over the years. Last year, he shared via Instagram that he was <a href="https://www.benzinga.com/personal-finance/25/04/45124694/mark-zuckerberg-says-his-wife-wanted-a-minivan-so-he-designed-a-porsche-hes-pretty-sure-should-exist-and-made-it-a-his-and-hers-set">designing a custom Porsche</a> as a special gift for his wife, Priscilla Chan. 
Describing it as a "new side quest," he revealed that the entire redesign was rooted in her preferences. Earlier in the same year, he <a href="https://www.benzinga.com/personal-finance/25/05/45241490/thats-weird-mark-zuckerberg-gifted-his-wife-a-7-foot-tall-turquoise-statue-of-herself-but-says-i-dont-think-she-was-that-happy-with-it">commissioned a marble statue of Chan</a>, posting a photo on Instagram with the caption: &#8220;Bringing back the Roman tradition of making sculptures of your wife.&#8221;
Despite these public expressions of family values and teaching his daughters about the importance of compassion for fellow human beings, Zuckerberg and Meta have faced repeated scrutiny for questionable business practices, such as measures undertaken to <a href="https://www.benzinga.com/general/social-media/25/03/44363736/zuckerbergs-global-push-meta-faces-scrutiny-over-privacy-free-speech-regulatory-tactics">infiltrate the Chinese market and employing lobbying tactics</a> in India; allegedly silencing ex-employees speaking out about issues like the company&#8217;s <a href="https://www.benzinga.com/25/03/44447618/facebook-whistleblower-says-mark-zuckerberg-led-metas-gag-order-is-silencing-her-from-speaking-to-congress-about-china-ties-teen-harm-and-harassment-claims">connections to China, harming teen users, and workplace misconduct</a> and <a href="https://www.benzinga.com/25/02/43723246/meta-faces-backlash-as-laid-off-workers-say-they-were-unfairly-targeted-despite-strong-performance-records">unfairly laying off workers</a> despite strong track records.  
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45338301/zuckerberg-foresees-tech-industry-revolution-with-ai-an-ai-that-can-effectively-be-a-sort-of-midlevel-engineer">Zuckerberg Foresees Tech Industry Revolution With AI: &#8216;An AI That Can Effectively Be a Sort of Midlevel Engineer&#8217;</a></li>
</ul>
Image Via Shutterstock

Social Media

Mark Zuckerberg's Bedtime Ritual With Daughters Max And August Reveals The Four Values He Wants To Pass Down—And Why He Calls It 'The Good Night Things'

HUB Cyber Security Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUBC#NASDAQ">HUBC</a>) ("HUB" or the "Company"), a developer of confidential computing cybersecurity solutions and services, today announced a series of new customer wins through its cybersecurity division, further expanding its footprint in high-risk, regulated industries including healthcare, financial services, and digital infrastructure.
The new engagements, signed over the first quarter of 2025 and collectively valued at over $1.5 million, underscore HUB's continued momentum in providing secured, compliant infrastructure to organizations facing increasingly complex data protection and regulatory challenges.

HUBC

HUB Cyber Security Lands $1.5M in New Contracts, Expanding in Healthcare and Financial Sectors

Imperial Metals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/III#TSX">III</a>) reported quarterly earnings of $0.26 per share. This is a 533.33 percent increase over losses of $(0.06) per share from the same period last year. The company reported $176.62 million in sales this quarter. This is a 108.85 percent increase over sales of $84.57 million the same period last year.

TSX:III

Imperial Metals Q1 Adj. EPS $0.26 Up From $(0.06) YoY, Sales $176.62M Up From $84.57M YoY

Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) sees Q2 sales of $100.000 million-$102.000 million vs $114.61 million analyst estimate.

Guidance

CHGG

Chegg Sees Q2 Sales $100.000M-$102.000M vs $114.61M Est

Mark Cuban, the billionaire entrepreneur, challenged Trump-supporter and political activist Charlie Kirk&#8216;s stance on high drug prices, asserting that Pharmacy Benefit Managers (PBMs) are the main culprits, not Big Pharma.
What Happened:&nbsp;Cuban criticized Kirk&#8217;s&nbsp;focus on Big Pharma as&nbsp;the primary driver of high drug prices. Instead, Cuban pointed to PBMs as the major offenders&nbsp;due to their opaque pricing&nbsp;practices and market dominance. Cuban highlighted the lack of transparency in PBMs&#8217; contracts, which often prohibit disclosing pricing details. He challenged&nbsp;Kirk to obtain a net&nbsp;price list from his company&#8217;s PBM. 
Meanwhile, Charlie Kirk, the founder of Turning Point USA, has regularly raised questions on the practices of Big Pharma through his posts and podcasts.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Charlie , you aren&#39;t close. Drug prices are too damn high. But the big culprit isn&#39;t the brand manufacturers, it&#39;s the big middlemen. Namely PBMs. They work so hard to distort pricing the first lines in their contracts with everyone is &quot;you can&#39;t disclose any of this &quot; How bad… <a href="https://t.co/oMnlvlOPtl">https://t.co/oMnlvlOPtl</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1921755430708969767?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cuban&#8217;s post aligns&nbsp;with a 2022 FTC investigation&nbsp;into PBMs&#8217;&nbsp;role in rising drug costs&nbsp;through practices like spread pricing. Moreover, according to a 2023 Bipartisan&nbsp;Policy Center, six PBMs control&nbsp;95% of the private market. 
He supports Trump's Executive Order to lower drug prices by 30-80%, suggesting that targeting PBMs, such as separating formularies and mandating claim disclosures, could make brand medications cheaper than in many countries, building on his own efforts with Cost Plus Drugs to cut out middlemen and reduce costs.
In one of his initial responses, Mark Cuban expressed support for the move, stating it could &#8220;force transparency,&#8221; even if the President can&#8217;t mandate price reductions.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/05/45338281/trump-has-a-proven-track-record-of-being-an-absolute-failure-says-gov-tim-walz-we-dont-need-to-run-governmen" target="_blank" rel="noreferrer noopener">Trump Has A &#8216;Proven Track Record Of Being An Absolute Failure,&#8217; Says Gov. Tim Walz—&#8217;We Don&#8217;t Need To Run Government Like A Business&#8217;</a>
Why It Matters: Cuban&#8217;s comments come in the wake of President Donald Trump&#8216;s announcement of a sweeping executive order aimed at slashing prescription drug prices. The order, which Trump referred to as the &#8220;most consequential executive order&#8221; in U.S. history, is set to implement a &#8220;Most Favored Nations&#8221; <a href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80">policy requiring</a> pharmaceutical companies to charge U.S. consumers no more than the lowest price they offer for the same drug in any other country.
Cuban, despite being a Trump critic, has <a href="https://benzinga.com/markets/25/04/44866755/mark-cuban-says-this-trump-healthcare-order-could-save-hundreds-of-billions">expressed support</a> for Trump&#8217;s healthcare order, emphasizing its potential to reform the role of PBMs in the U.S. healthcare system and save billions. He believes&nbsp;that targeting PBMs—such as separating&nbsp;formularies and mandating claim disclosures—could&nbsp;make brand medications cheaper than&nbsp;in many countries.
Meanwhile, Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) were trading 2% to 5% lower in Monday&#8217;s premarket in response to Trump&#8217;s executive order.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45328061/bitcoin-ethereum-xrp-dogecoin-enter-weekend-strong-long-dips-140000-is-programmed-trader-says" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, XRP, Dogecoin Enter Weekend Strong: &#8216;Long Dips, $140,000 Is Programmed,&#8217; Trader Says &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

General

Mark Cuban Slams Charlie Kirk Over Drug Price Debate, Says PBMs — Not Big Pharma — Are The Real Villains: 'For Your Company…Ask Your PBM For A List Of Claims'

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) with a Buy and maintains $30 price target.

IBRX

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) reported quarterly losses of $(0.06) per share. This is a 123.08 percent decrease over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $121.39 million which beat the analyst consensus estimate of $114.61 million by 5.92 percent. This is a 30.38 percent decrease over sales of $174.35 million the same period last year.

Earnings Beats

Chegg Q1 Adj. EPS $(0.06) Down From $0.26 YoY, Sales $121.39M Beat $114.61M Estimate

– ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints –
– MSA Atrophy Index (MSAai) enhances MSA diagnosis and monitoring –
– bioMUSE Study shows higher α- synuclein concentration is associated with greater burden of orthostatic symptoms –
MELBOURNE, Australia and SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:<a href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that several oral and poster presentations related to Alterity's clinical programs in Multiple System Atrophy (MSA) were featured at the 2025 International MSA Congress. The Congress was presented by Mission MSA, a non-profit organization dedicated to improving the quality of life and building hope for people affected by MSA through support services, educational resources, research funding, and community engagement.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Alterity Therapeutics Presents MSA Research At 2025 International MSA Congress; ATH434 Phase 2 Data Shows Clinically Meaningful Efficacy On Multiple Clinical Endpoints

ZCAR

Zoomcar Names Automotive Veteran Deepankar Tiwari As CEO, Aims To Deepen Market Presence And Enhance User Experience

Needham analyst Charles Shi maintains Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) with a Buy and lowers the price target from $19 to $10.

SVCO

Needham Maintains Buy on Silvaco Group, Lowers Price Target to $10

The patent application relates to a combination treatment using Clearmind's 5-methoxy-2-aminoindane ("MEAI") and SciSparc's Palmitoylethanolamide for the treatment of cocaine addiction.

Biotech

CMND

SPRC

SciSparc Announced That Its Collaboration With Clearmind Medicine Has Led To The Publication Of A European Patent Application By The European Patent Office

ACON

Aclarion Adds Texas Back Institute As New CLARITY Trial Site

Gain Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a guided poster presentation was made at the International Association of Parkinsonism and Related Disorders (IAPRD) 30th World Congress on Parkinson's Disease and Related Disorders, held May 7th-10th in New York City, NY. The poster outlined new evidence supporting GT-02287's ability to provide a broader neuroprotective effect and potential as a disease-modifying therapy for Parkinson's disease.

GANX

Gain Therapeutics Presents GT-02287 Data Highlighting Neuroprotective Potential As Disease-Modifying Therapy For Parkinson's Disease At IAPRD 2025

<ul>
<li>Presentation Underscores Deep Track's Value Destructive Plan and Inferior Slate of Director Nominees</li>
<li>Urges Stockholders to Vote&nbsp;"FOR"&nbsp;All Four Dynavax Director Nominees on the&nbsp;GOLD&nbsp;Proxy Card Today</li>
</ul>

DVAX

Dynavax Defends Strategic Direction, Highlights Vaccine Leadership And Capital Returns In Proxy Fight With Deep Track

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTS and HURA on Behalf of Shareholders

Events

Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

TuHURA Biosciences, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

Management

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors

Small Cap

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)

Comments

TuHURA Biosciences

Noticias

Últimas noticias sobre TuHURA Biosciences (NASDAQ:HURA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL